Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: A multicenter, randomized study in Japan

Journal of Infection and Chemotherapy

Volumn 19, Issue 6, 2013, Pages 1035-1041

  Kohno, Shigeru ^a   Yanagihara, Katsunori ^a,b   Yamamoto, Yoshihiro ^a   Tokimatsu, Issei ^c   Hiramatsu, Kazufumi ^c   Higa, Futoshi ^d   Tateyama, Masao ^d   Fujita, Jiro ^d   Kadota, Jun Ichi ^c  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c OITA UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Community acquired pneumonia; Garenoxacin; Switch therapy

Indexed keywords

C REACTIVE PROTEIN; GARENOXACIN; SULTAMICILLIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; FOOD INTAKE; HOSPITAL PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SCORING SYSTEM; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RECURRENCE; SULBACTAM; TREATMENT OUTCOME;

EID: 84890858235     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0618-5     Document Type: Article

References (16)

1. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-6.
2. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother. 1995;29:561-5.
3. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-54.
4. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, Armengou-Arxé A, Bisbe-Company V, Peñarroja-Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111:367-74.
5. Cunha BA. Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Am J Med. 2001;111:412-3.
6. Yanagihara K, Morinaga Y, Yamada K, Nakamura S, Kurihara S, Yamamoto K, et al. Efficacy of switch therapy in community-acquired pneumonia in Japan. Jpn J Chemother. 2009;57:423-9.
7. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
8. Grohs P, Houssaye S, Aubert A, Gutmann L, Varon E. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob Agents Chemother. 2003;47:3542-7.
9. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47:1867-74.
10. Christiansen KJ, Bell JM, Turnidge JD, Jones RN. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother. 2004;48:2049-55.
11. Jones RN, Fritsche TR, Sader HS, Stilwell MG. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis. 2007;58:9-17.
12. Uchida E. Phase 1 clinical studies of oral garenoxacin in healthy Japanese adult subjects. Jpn J Chemother 2007;55(S-1):95-115.
13. Watanabe A, Niitsuma K, Takeda H, Aoki N. Penetration into sputum study of garenoxacin in patients with secondary infection of chronic respiratory disease. Jpn J Chemother 2007;55(S-1):162-8.
14. Tanigawara Y, Nozawa K, Tsuda H. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation. Eur J Clin Pharmacol. 2012;68:39-53.
15. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-54.
16. Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology. 2008;13:880-5.